Table 1. Patient Characteristics Patient... | American Society of Hematology

Table 1.

Patient Characteristics

Patient No.	Age/Sex at Time of DLI	MM Stage at Diagnosis	Disease Status at BMT	Lines of Previous Chemotherapy (n)	Conditioning^*	Date of BMT (MM/DD/YY)	Donor Sex	TCD	GVHD Post-BMT (acute/chronic)	Response to BMT	Relapse/Progression mo Post-BMT
1	49/F	2A	Resistant	2	a	04/03/92	F	+1	0/nil	PR	15
2	45/M	2A	Resistant	3	a	09/04/91	M	+1.1	1/limited	NR	15
3	47/M	1A	PR	1	d	07/20/94	M	+0.6	0/nil	CR	8
4	37/M	1A	Resistant	1	a	06/18/87	M	+1	0/nil	PR	87
5	53/M	3A	PR	2	a	08/01/92	M	+1	2/nil	PR	25
6	37/F	2A	PR	1	a	05/09/90	F	+0.8	1/limited	CR	60
7	50/M	3A	Resistant	1	b	12/02/92	M	+0.9	0/nil	NR	25
8	47/M	3A	Resistant	2	c	06/28/95	F	+1	0/nil	CR	5
9^†	43/F	2A	PR	1	a	05/18/88	M	+1.3	1/limited	CR	63
10	55/M	3A	Resistant	1	a	07/21/95	F	+1	1/nil	PR	9
11	49/F	2A	PR	2	a	08/27/93	M	+1	1/nil	PR	27
12	44/M	3A	Resistant	2	a	06/16/95	M	+1	2/limited	PR	11
13	40/M	3A	PR	2	a	01/11/96	M	+1	2/limited	PR	8

Patient No.	Age/Sex at Time of DLI	MM Stage at Diagnosis	Disease Status at BMT	Lines of Previous Chemotherapy (n)	Conditioning^*	Date of BMT (MM/DD/YY)	Donor Sex	TCD	GVHD Post-BMT (acute/chronic)	Response to BMT	Relapse/Progression mo Post-BMT
1	49/F	2A	Resistant	2	a	04/03/92	F	+1	0/nil	PR	15
2	45/M	2A	Resistant	3	a	09/04/91	M	+1.1	1/limited	NR	15
3	47/M	1A	PR	1	d	07/20/94	M	+0.6	0/nil	CR	8
4	37/M	1A	Resistant	1	a	06/18/87	M	+1	0/nil	PR	87
5	53/M	3A	PR	2	a	08/01/92	M	+1	2/nil	PR	25
6	37/F	2A	PR	1	a	05/09/90	F	+0.8	1/limited	CR	60
7	50/M	3A	Resistant	1	b	12/02/92	M	+0.9	0/nil	NR	25
8	47/M	3A	Resistant	2	c	06/28/95	F	+1	0/nil	CR	5
9^†	43/F	2A	PR	1	a	05/18/88	M	+1.3	1/limited	CR	63
10	55/M	3A	Resistant	1	a	07/21/95	F	+1	1/nil	PR	9
11	49/F	2A	PR	2	a	08/27/93	M	+1	1/nil	PR	27
12	44/M	3A	Resistant	2	a	06/16/95	M	+1	2/limited	PR	11
13	40/M	3A	PR	2	a	01/11/96	M	+1	2/limited	PR	8

Abbreviation: TCD, T-cell dose ×10⁵/kg.

a, 120 mg/m² cyclophosphamide + TBI; b, ifosfamide + melphalan; c, busulfan + cyclophosphamide; d, idarubicine + cyclofosfamide + TBI.

Haploidentical sibling BMT, all other patients genotypically identical sibling.